Categories Consumer, Earnings

Earnings: Signet Jewelers turns to loss in Q4 as same-store sales fall

Signet Jewelers (SIG) posted its fourth-quarter 2019 earnings before the opening bell on Wednesday, April 3. Total sales in the quarter slipped 6% to $2.15 billion, while total same-store sales fell 2% year-over-year.

Signet reported a GAAP loss of $2.25 per diluted share, versus the previous-year profit of $5.24 a share. Non-GAAP Diluted EPS, however, slumped 7.5% to $3.96 per share.

The same store sales performance included the favorable impacts of about 60 bps related to incremental clearance, and about 35 bps due to planned shifts in timing of promotions at Zales and Peoples, and a 25 bps unfavorable impact related to a timing shift of service plan revenue recognized as a result of the historical claims experience shifting away from the earlier years of the service plans to later years of the coverage period.

Signet Jewelers fourth quarter 2019 Earnings Infographic

North America payment plan participation rate — including both credit and leasing sales — reached 50.1% from 49.7% a year ago.

eCommerce sales in the quarter grew 5.4% to $260.6 million, with the eCommerce sales accounted for 12.1% of fourth-quarter sales. Brick and mortar same-store sales slipped 3% in the period.

Despite turning to a loss in the fourth quarter, Signet still sees GAAP diluted EPS of $1.86-2.66 and non-GAAP diluted EPS of $2.87-3.45 in the coming fiscal 2020. While maintaining a quarterly dividend of 37 cents a share, Signet expects same-store sales to be down 2.5% to flat, and total sales to be between $6.0 billion to $6.1 billion.

Talking about North America sales in the currently reported fourth-quarter, the geography’s same-store sales slipped 1.4%. International same-store sales fell further — down 7.3%.

 

 

 

Earnings Calendar: Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top